



易贸生物产业大会  
合作加速创新

BIOCHINA2024 will be held at Halls ABCDEFG of the Suzhou International Expo Center from March 14-16, 2024.

In 2023, from R&D, clinical to production, and then to commercialization; from Biotech, to CXO, and then to domestic upstream suppliers of biological medicine, overseas topics will expand from more dimensions. In 2023, the wave of domestic ADC license out has swept across, MNC and domestic Biotech cooperation models become increasingly diverse, BD cooperative projects and total amount hit new heights again.

**Innovation** has become an enduring direction under policy encouragement.

**Cooperation** has become the inevitable choice driven by market iteration and development.

Here, the 9th ENMORE Bio Exhibition (EBC) will be renamed BIOCHINA.

## BIO CHINA

We will lead global bio-industry colleagues to focus on China. We hope to convey "Cooperation Accelerates Innovation" with global bio-industry colleagues.

## Cooperation Accelerates Innovation

BIOCHINA2024 (EBC) sets sail with three major systems - **exhibitions, conferences and events**, with a scale of **30,000 people, 550 exhibitors, and 500 academic speeches**. Under the joint planning and promotion of cooperative institutions and content partners, we will further develop innovative technologies and product development, focus on domestic and foreign project cooperation and business expansion, and promote cooperation and exchanges between Chinese biomedical enterprises and global partners.



## Exhibitions

50,000 square meters of professional BIO exhibitions accurately connecting upstream and downstream industries

## Conferences

All-industry, multi-functional, multi-level professional forums, technology and business trend indicators

## Events

Competitions, visits, sports, cocktail parties, mini marathon, immersive check-in BIOCHINA

domestic exhibitors  
500

scientific research institutes  
500

overseas exhibitors  
50

domestic Biotech companies  
3,000

overseas Biotech companies  
100

visitor representatives  
30,000

speakers  
800

Pre-scheduled Meetings  
10,000

business executives  
3,000

high-level forums  
100

featured events  
50

technical backbones  
20,000






# About the Exhibition

55,000 square meters of professional BIO exhibitions accurately connecting upstream and downstream industries



## The 9th ENMORE Bio Exhibition 2024





# About the Events




**10000**  
meeting requests



**50**  
featured events

Accelerate business cooperation and partnership discussions between domestic and overseas Biotech, Pharma and investment institutions



# Partners

## ◆ Guiding Unit ◆



苏州市科学技术局

## ◆ Partners ◆





## Science Committee Members

Liu Yongjun, President of Innovent Biologics, Tang Aoqing Guest Professor of Jilin University	Dong Chen, Academician of Chinese Academy of Sciences, Dean of Medical School of Westlake University
Shao Feng, Academician of Chinese Academy of Sciences, Deputy Director of National Institute of Biological Sciences, Beijing, Tenured Professor of Tsinghua University, Founder of Pyrotech Therapeutics	Su Bing, Wang Kuan-Cheng Chair Professor of Shanghai Jiao Tong University, Director of Shanghai Institute of Immunology

## Expert Committee Members (in alphabetical order)

Cai Daqing, Founding Managing Partner, Sherpa Healthcare Partners	Fang Jianmin, Co-Founder, CEO, RemeGen Co., Ltd.	Ge Junyou, CEO, Kelun Biotech
Gong Zhaolong, Chairman & CEO, 3D Medicines	Huang Hai, CEO, Fosun Kite	Li Bin, Chairman & CEO, neurophth
Li Jin, Professor, Shanghai East Hospital	Li Ning, GM, Junshi Biosciences	Li Yiping, CEO, JW Therapeutics
Liu Datao, CEO, Mabwell Biosciences	Tao Weikang, VP of Qilu Pharma, GM of Global Innovative Drug R&D Center, Qilu Pharmaceutical	Ying Bo, Founder & CEO, ABOGEN
Zhang Jinhua, Chairman & CEO, IASO Biotherapeutics	Zhang Lianshan, Director, Deputy GM, Hengrui Pharmaceutical	

## Planners (in alphabetical order)

Cao Xiaoping, Senior Vice President, JW Therapeutics	Cui Wenwen, Founder & Editor-in-Chief, RNAScript	Deng Mi, Researcher, International Cancer Research Institute of Beijing University
Fan Jing, Founder & CEO, Hopstem Biotech	Fang Yan, Senior Director of Shanghai Bio-tech Development, Qilu Pharmaceutical	Gao Dong, Deputy Dean of Research Institute, BioRay
Bu Peng, VP of Nucleic Acid Sciences, ABOGEN	Gu Jinming, VP of R&D China, Legend Biotech	Gu Chunyu, Founder, Chairman of Board, Allife Medicine
Han Dongmei, Executive Director, Hansoh Pharma	Huang Jinyu, VP of Chemistry, RONA Therapeutics	Huang Wei, Chief Medical Officer of Oncology, CSPC Pharmaceutical Group
Li Hao, Senior Director, Hengrui(Shanghai)	Li Huiming, Deputy GM of New Drug R&D Center, Kexing Biopharm	Li Jin, GM of Regulatory Affairs, Henlius Biotech
Li Qiutang, CSO, Neurophth	Liu Dayou, CEO, Ange Biotech	Liu Ding, Deputy GM, Qilu Pharmaceutical Biotech
Lu Renhao, Senior Director of Quality, Ex-tect	Ni Hua, VP, Mabwell Biosciences	Shan Bo, CSO, Antengene
Shen Huaqiong, Founder & CEO, Neushen Therapeutics	Song Zhenbo, Department Director of Phase I Clinical Ward & PhD Supervisor, Zhejiang Cancer Hospital	Tong Jing, Executive Director, Junmeng Biopharm
Wang Min, VP, PersonGen	Wang Yefei, VP of Pharmaceutical Sciences, Gmax Biopharm	Wang Yongzeng, CTO, Juventas Bio
Wen Danyi, Chairman & CEO, LIDE Biotech	Xie Chao, Senior Director, Pfizer (China) Research and Development Co., Ltd.	Xie Wan, GM, Junshi Biosciences Engineering
Xu Ge, Quality Head, JW Therapeutics	Yang Fan, Deputy Director of Automation, BeiGene	Yuan Fanyu, CMC Director, ChainGen Biopharma
Zhang Jian, Administrative Director of Phase I Clinical Ward, Fudan University Cancer Hospital	Zhang Junli, Senior VP, ZenCore biologics	Zheng Hao, CSO, Belief BioMed
Zhou Hui, Senior VP, Innovent Biologics	Zhou Jingmin, CEO & Co-Founder, Genemagic Biosciences	Zhou Li, CSO, Juventas Bio
Zhou Wei, Director of ADC Drug R&D Department, Mabwell Biosciences	Zhu Jun, CEO, Henlius Biotech	



## Conference agenda

	Conference Name	<b>BIOCHINA2024 (EBC) Scientists Summit</b> Chairs: Liu Yongjun, Dong Chen, Shao Feng, Su Bing
<b>March 15, Full Day</b>	<b>Content</b>	<p>10:00-10:45 Opening Remarks &amp; Speech: Liu Yongjun, President of Innovent Biologics, Tang Aoqing Guest Professor of Jilin University</p> <p>10:45-10:50 Q&amp;A</p> <p>10:50-11:30 Speech: Metabolic and Neural Regulation of Immunity and Cancer</p> <p>Speaker: Tak W. Mak, Director, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University of Toronto</p> <p>11:30-11:35 Q&amp;A</p> <p>11:35-12:15 Speech: Dong Chen, Academician of Chinese Academy of Sciences, Dean of Medical School of Westlake University</p> <p>12:15-12:20 Q&amp;A</p> <p>13:15-14:30 Panel Discussion:</p> <p>Liu Yongjun, President of Innovent Biologics, Tang Aoqing Guest Professor of Jilin University</p> <p>Dong Chen, Academician of Chinese Academy of Sciences, Dean of Medical School of Westlake University</p> <p>Shao Feng, Academician of Chinese Academy of Sciences, Deputy Director of National Institute of Biological Sciences, Beijing, Tenured Professor of Tsinghua University, Founder of Pyrotech Therapeutics</p> <p>Su Bing, Wang Kuan-Cheng Chair Professor of Shanghai Jiao Tong University, Director of Shanghai Institute of Immunology</p> <p>14:30-15:10 Speech: NLRP3 inflammasome biology - from bench to bedside</p> <p>Speaker: Eicke Latz, Scientific Director, Deutsches Rheuma Forschungszentrum Berlin</p> <p>15:10-15:15 Q&amp;A</p> <p>15:15-15:55 Speech: Shao Feng, Academician of Chinese Academy of Sciences, Deputy Director of National Institute of Biological Sciences, Beijing, Tenured Professor of Tsinghua University, Founder of Pyrotech Therapeutics</p> <p>15:55-16:00 Q&amp;A</p> <p>16:00-16:40 Speech: Su Bing, Wang Kuan-Cheng Chair Professor of Shanghai Jiao Tong University, Director of Shanghai Institute of Immunology</p> <p>16:40-16:45 Q&amp;A</p> <p>16:45-17:25 Speech: A Novel Metabolic Checkpoint That Controls Progression From Hepatocyte Senescence to Cancer</p> <p>Speaker: Michael Karin, Distinguished Professor of Pharmacology, University of California, San Diego (UCSD)</p> <p>17:25-17:30 Q&amp;A</p>



Time	BIOCHINA2024 (EBC) Industry Focus Forums									BD & Investment Forums		
March 15 PM	Forum Names	BIOCHINA2024 Antibody Industry Focus	BIOCHINA2024 Cell Therapy Focus	BIOCHINA2024 Nucleic Acid Drugs Focus	BIOCHINA2024 Gene Therapy Focus	BIOCHINA2024 AI Technology Focus	BIOCHINA2024 CBO Summit	BIOCHINA2024 Raw Materials Industry Focus	BIOCHINA2024 Procurement Summit	March 14 Full Day	BioFunding	BioBD
	Content	Bispecific antibodies	Clinical needs and applications Expansion Commercialization challenges	R&D progress Industrialization challenges	Clinical progress	AI drug clinical progress	Reimbursement and access Domestic commercialization Overseas commercialization	Technology development Product layout Overseas strategy	Procurement trends		Roadshows Meetings	Meetings
March 16 AM	Forum Names	BIOCHINA2024 ADC Industry Focus	BIOCHINA2024 Cell Therapy Focus	BIOCHINA2024 Vaccine Industry Focus	BIOCHINA2024 Gene Therapy Focus	BIOCHINA2024 Peptide Drugs Focus	BIOCHINA2024 Overseas Market Strategy	BIOCHINA2024 Synthetic Biology Focus	BIOCHINA2024 Procurement Summit	March 15 Full Day	BioFunding	BioBD
	Content	Commercialization	Manufacturing and change	R&D progress	Technical platform	GLP-1 Long-acting peptide /cyclic peptide	Middle East Australia Singapore	Technical progress and application	Supply chain management		CEO Forum Meetings	Forums Meetings
March 16 PM	Forum Names	XDC R&D Focus	BIOCHINA2024 Stem Cell Drug Focus	BIOCHINA2024 Vaccine Industry Focus	BIOCHINA2024 Organoids Focus	BIOCHINA2024 Small Molecule Innovative Drug Focus	BIOCHINA2024 Overseas Market Strategy	BIOCHINA2024 Instruments & Equipment Focus	BIOCHINA2024 Procurement Release	March 16 Full Day	BioFunding	BioBD
	Content	R&D progress	Clinical needs R&D progress Industrialization challenges	Commercialization	Case sharing	Technical platform Formulation development	Korea Russia India	Automation and intelligence Localization	Demand release		Roadshows Meetings	Forums Meetings
Time	Early R&D & Tech Transfer Sub-forums				Preclinical & Clinical Sub-forums				CMC Development & Manufacturing Sub-forums			
March 16 PM	Forum Names	Academia Tech Transfer Forum	Early R&D Forum	CSO Summit	Clinical Development Forum	Clinical Development Forum	Clinical Development Forum	Clinical Development Forum	Process Development Forum	Formulation Development Forum	Quality & Analysis Forum	simulated factory
	Content	Mechanism research	Target-based innovative drug R&D	Development of differenttherapies against hot targets	Latest IND progress release	Biosimilar registration strategy and case studies	Global multi-regional regulations	Phase I clinical trial design for ADC niche products or indications	Cell and gene therapy	Novel formulation development	Antibody drugs	Building real objects Immersive experience
March 16 PM	Forum Names	Academia Tech Transfer Forum	Early R&D Forum	Early R&D Forum	Preclinical Research Forum	CMO Summit	CRO Industry Focus	Clinical Development Forum	Process Development Forum	Formulation Development Forum	Quality & Analysis Forum	Manufacturing Facility Construction Forum
	Content	Technical platforms	Molecular design and mechanism research	Preclinical research progress release	Animal models	Global clinical development strategies Phase III clinical challenges	Clinical development service challenges	Differentiated development between MNCs and domestic pharmas	Antibody drugs	New technologies and applications	Cell and gene therapy	Automated manufacturing facilities
March 16 PM	Forum Names	Academia Tech Transfer Forum	Early R&D Forum	XDC R&D Focus	Preclinical Research Forum	Clinical Development Forum	Clinical Development Forum	Clinical Development Forum	Process Development Forum	Process Development Forum	Quality & Analysis Forum	Commercial Manufacturing Forum
	Content	Indications	Cell and gene design and mechanism research	R&D progress	Preclinical evaluation of different therapies	International multi-center operations	Oncology drug development case sharing	Non-oncology drug development case sharing	ADC	Nucleic acid drugs	Cell and gene therapy	Tech transfer



## Overview of Early R&D and Preclinical Research Related Forums at BIOCHINA2024 (EBC)

March 15 AM	Forum Name	BIOCHINA2024 Academia Tech Transfer Forum Mechanism research	BIOCHINA2024 Early R&D Forum Target-based innovative drug R&D	/	/
	Content	New target discovery mechanisms Latest findings in signaling pathways for complex indications latest research on drug delivery methods	innovative target screening technology platforms (proteomics, CRISPR, transposons) <a href="#">Planner: Li Huiming, Deputy GM of New Drug R&amp;D Center, Kexing Biopharm</a>	/	/
March 15 PM	Forum Name	BIOCHINA2024 Academia Tech Transfer Forum New technology applications	BIOCHINA2024 Early R&D Forum Target-based innovative drug R&D	BIOCHINA2024 Antibody Industry Focus Forum Bispecific antibody drug development	BIOCHINA2024 Early R&D Forum Preclinical research progress release
	Content	Transfection technologies (cell, viral) Nanobody technologies In vivo CAR technologies	Target discovery and compound development <a href="#">Planner: Shan Bo, CSO, Antengene</a> · Differentiated development strategies for validated targets · Strategies for completely novel targets · Development strategies for compounds and antibodies after target confirmation Drug target discovery and drug design for ophthalmic rare diseases <a href="#">Planner: Li Qitang, CSO, Neuropht</a> · Leber hereditary optic neuropathy (target discovery, drug design and validation) · Autosomal dominant optic atrophy target discovery, drug design and validation	Innovative molecular design Molecular evaluation	Breakthrough preclinical progress across sectors
March 16 AM	Forum Name	BIOCHINA2024 Academia Tech Transfer Forum Technology platforms	BIOCHINA2024 Early R&D Forum Molecular design and mechanism research	BIOCHINA2024 Antibody Industry Focus Forum XDC drug development	BIOCHINA2024 Preclinical Research Forum Animal models
	Content	Novel CAR cell therapy systems ADC platforms Universal cell therapy platforms	Cell therapy molecular design and mechanisms <a href="#">Planner: Gu Jinming, VP of R&amp;D China, Legend Biotech</a> Gene editing platforms iPSC technology platforms <a href="#">Planner: Gu Chunyu, Founder, Chairman of Board, Allife Medicine</a>	Radioimmunoconjugates (RICs) Antibody oligonucleotide conjugates (AOCs) Peptide drug conjugates (PDCs)	Target development models Pharmacodynamics models Toxicology models
March 16 PM	Forum Name	BIOCHINA2024 Academia Tech Transfer Forum Indications	BIOCHINA2024 Early R&D Forum Molecular design and mechanism research	BIOCHINA2024 CSO Summit	BIOCHINA2024 Preclinical Research Forum Different therapies
	Content	Glioblastoma Neurological diseases Cardiovascular diseases	ADC molecular design and mechanisms Bispecific molecular design and mechanisms	Platform layouts Collaboration mechanisms Development strategies	ADC drug preclinical research Cell therapy preclinical research Gene therapy preclinical research

## Overview of Clinical and Late-stage Preclinical Related Forums at BIOCHINA2024 (EBC)

	Forum Name	BIOCHINA2024 Clinical Development Forum Global Market	BIOCHINA2024 Clinical Development Forum Global Multi-Regional Regulations	BIOCHINA2024 Clinical Development Forum ADC	BIOCHINA2024 Clinical Development Forum Latest IND Progress Release
March 15 PM	Content	Planner: Zhu Jun, CEO, Henlius Biotech Biosimilar registration strategies and case studies Overseas market clinical strategies	Planner: Chinese Biopharma Association USA Global multi-regional submission case sharing	Planner: Song Zhenbo, Department Director of Phase I Clinical Ward & PhD Supervisor, Zhejiang Cancer Hospital Researcher and sponsor discussion on ADC Planner: Zhang Jian, Administrative Director of Phase I Clinical Ward, Fudan University Cancer Hospital Phase I clinical trial design for ADC niche products or indications Planner: Zhou Hui, Senior VP, Innovent Biologics ADC clinical development strategies	Latest IND progress across sectors and indications
	Forum Name	BIOCHINA2024 CMO Summit Global Development Strategies	BIOCHINA2024 CRO Industry Focus Clinical Development Service Challenges	BIOCHINA2024 Clinical Development Forum Differentiated development between MNCs and domestic pharmas	BIOCHINA2024 Preclinical Research Forum Animal Models
March 16 AM	Content	Interviews on global clinical development strategies Interviews on Phase III challenges Interviews on clinical challenges for new therapies and indications	Report: Current status of CRO industry Interviews on global clinical development challenges Interviews on extending CRO service value chain Interviews on potential demands and collaborativedevelopment in niche areas	Planner: Xie Chao, Senior Director, Pfizer (China) Oncology drug development strategies Autoimmune disease development strategies Metabolic disease development strategies	Target development models Pharmacodynamics models Toxicology models
	Forum Name	BIOCHINA2024 Clinical Development Forum International Multi-center Operations	BIOCHINA2024 Clinical Development Forum Oncology Drug Development Case Sharing	BIOCHINA2024 Clinical Development Forum Non-oncology Drug Development Case Sharing	BIOCHINA2024 Preclinical Research Forum Innovative Therapy Research Case Sharing
March 16 PM	Content	International multi-center strategies and regulations International multi-center case sharing 1 Planner: Huang Wei, Chief Medical Officer of Oncology, CSPC Pharmaceutical Group International multi-center case sharing 2	Planner: Wen Danyi, Chairman & CEO, LIDE Biotech Perspectives from PIs Failed case studies Overseas case studies	Zhang Jing, Phase I Clinical Research Ward, Huashan Hospital of Fudan. University Anti-infective drugs Li Haiyan, Cardiovascular, Third Hospital of Peking University (TBC) Cardiovascular drugs Shanghai Mental Health Center (TBC) Psychiatric drugs	ADC drug preclinical research Cell therapy preclinical research Gene therapy preclinical research